Scrap Citizen Petition Proposal For 505(b)(2), Off-Patent Industry Urges FDA
Citizen Petitions Can ‘Languish Unanswered’ For Years
Executive Summary
Several stakeholders across the off-patent industry, including trade groups and manufacturers, have encouraged the FDA to scrap its proposal to require companies to submit citizen petitions for requesting therapeutic equivalence evaluations for 505(b)(2) applications.
You may also be interested in...
Therapeutic Equivalence Evaluations Would Be Required For 505(b)(2) Drugs Under Senate User Fee Bill
The Senate HELP Committee added a therapeutic equivalence provision to the draft measure it floated two weeks ago. The bill introduced in the Senate still does not include provisions on clinical trial diversity or 180-day exclusivity.
Hexarad: Building A Professional Community Of Remote-Working Radiologists
British teleradiology provider Hexarad has shot from strength to strength in recent years, launching two different programs and opening up opportunities for its network of radiologists to continue supporting the National Health Service while working abroad. Company CEO Farzanah Rahman, one of In Vivo’s 2023 Rising Leaders, discussed Hexarad’s expansion, its values and the myth of the sole leader.
AMR Alliance Follows Up Global Industry Standard With Responsible Manufacturing Certification
A new voluntary certification from the AMR Industry Alliance and the British Standards Institution will assess pharmaceutical firms’ responsibility and sustainability when it comes to manufacturing antibiotic drugs, in an attempt to control the spread of antimicrobial resistance.